Portfoliotracker

Sight Sciences, Inc.

SGHT · NASDAQGS · Healthcare Medical Devices 6/100 E

10,59 $
▼ −0,24 (−2,22 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 14:51
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score6 / 100 Market cap584 mil. $ P/E– Forward P/E-29,5 P/S6,6 P/B11,9 EV/EBITDA– Dividend yield– FCF yield-2,90 % EPS-0,52 $ Net margin-32,1 % Return on equity-50,1 % Beta2,40 Debt / equity0,86
52-week range 3,38 to 11,60
3-month average volume0,3 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Employees
186
Country
United States
Fiscal year end
31. 12.
Data since
15. 7. 2021

Explore further

Similar companies CTKBTMCIRXSTDSGN

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account